Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence <i>In Vitro</i>
Rima Acosta, Michelle L. D’Antoni, Andrew Mulato, Stephen R. Yant, Tomáš Cihlář, Kirsten White
Abstract
The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), dolutegravir (DTG)+FTC/TAF, DTG/lamivudine (3TC), and DTG/rilpivirine (RPV) are all approved for treatment of HIV-infected patients, with various limitations. Here, time to in vitro viral breakthrough (VB) and resistance barrier using simulated human drug exposures at either full or suboptimal treatment adherence to each regimen were compared.
Topics & Concepts
CminDolutegravirEmtricitabineRilpivirineTenofovir alafenamidePharmacologyRegimenMedicineVirologyIntegrase inhibitorDrug resistanceIntegrasePharmacokineticsCmaxHuman immunodeficiency virus (HIV)BiologyInternal medicineViral loadMicrobiologyAntiretroviral therapyHIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and Interventions